Derma Sciences (DSCI) Prelim. Q4, FY15 Sale Miss Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- Intel shares fall as competitor reports record results
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Oppenheimer Cuts Price Target Following Derma Sciences' (DSCI) 4Q Preliminary Results
January 8, 2016 9:23 AM ESTOppenheimer maintained an Outperform rating on Derma Sciences (NASDAQ: DSCI), and cut the price target to $7.00 (from $8.00), following the company's preliminary 4Q15 results. 4Q sales were ~$1.9M below on Advanced Wound Care (AWC) and ~$1.5M below on Traditional Wound Care (TWC).
Analyst Steven Lichtman... More
Canaccord Genuity Downgrades Derma Sciences (DSCI) to Hold
January 7, 2016 9:43 AM ESTCanaccord Genuity downgraded Derma Sciences (NASDAQ: DSCI) from Buy to Hold.
For an analyst ratings summary and ratings history on Derma Sciences click here. For more ratings news on Derma Sciences click here.
Shares of Derma Sciences closed at $4.32 yesterday.
... More


